Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DUSTIN B FELDMAN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1689894867
CMS profile
31445
Location
FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,481.54

114 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,481.54 114

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DUSTIN B FELDMAN

NPI 1689894867 · CMS profile ID 31445

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689894867?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DUSTIN B FELDMAN, NPI 1689894867, CMS profile ID 31445. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689894867?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DUSTIN B FELDMAN, NPI 1689894867, CMS profile ID 31445. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689894867?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DUSTIN B FELDMAN, NPI 1689894867, CMS profile ID 31445, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1689894867?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

114 matching records · $2,481.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 114 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 114.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $13.1807/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111573360 CMS
Kiniksa Pharmaceuticals International, plc $21.5507/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154886739 CMS
Alnylam Pharmaceuticals Inc. $19.3407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125845230 CMS
AstraZeneca Pharmaceuticals LP $14.1707/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104722655 CMS
Merck Sharp & Dohme LLC $20.7107/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141852417 CMS
PFIZER INC. $37.1007/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131527328 CMS
SCPHARMACEUTICALS INC. $19.2807/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132285492 CMS
Novo Nordisk Inc $18.9406/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097359912 CMS
Amgen Inc. $13.8706/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111573358 CMS
Abbott Laboratories $137.3406/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125199676 CMS
Janssen Pharmaceuticals, Inc $15.3406/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078055654 CMS
Alnylam Pharmaceuticals Inc. $24.6906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125845218 CMS
Lexicon Pharmaceuticals, Inc. $23.7206/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081712375 CMS
Novartis Pharmaceuticals Corporation $21.5306/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086868081 CMS
Merck Sharp & Dohme LLC $22.9105/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141852421 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.9205/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118112951 CMS
E.R. Squibb & Sons, L.L.C. $19.6105/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101238378 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $7.3905/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118112945 CMS
Amgen Inc. $13.5205/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111573356 CMS
Merck Sharp & Dohme LLC $24.0305/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141648924 CMS
PFIZER INC. $27.4205/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131466955 CMS
Novartis Pharmaceuticals Corporation $24.6305/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086868077 CMS
Alnylam Pharmaceuticals Inc. $19.6305/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125845198 CMS
Alnylam Pharmaceuticals Inc. $3.3305/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125845200 CMS
Alnylam Pharmaceuticals Inc. $0.3205/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125845196 CMS
Janssen Pharmaceuticals, Inc $17.0205/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078055704 CMS
E.R. Squibb & Sons, L.L.C. $12.9004/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101238362 CMS
Novartis Pharmaceuticals Corporation $27.4404/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086868075 CMS
Amgen Inc. $13.7804/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111573354 CMS
Novo Nordisk Inc $17.2204/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097409796 CMS
Lexicon Pharmaceuticals, Inc. $29.2304/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081712377 CMS
Novartis Pharmaceuticals Corporation $23.1404/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086868071 CMS
Daiichi Sankyo Inc. $24.5303/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089420876 CMS
E.R. Squibb & Sons, L.L.C. $35.0903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101238358 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.7203/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118112961 CMS
AstraZeneca Pharmaceuticals LP $15.2503/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104758562 CMS
Amgen Inc. $10.9903/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111573352 CMS
Janssen Pharmaceuticals, Inc $18.5503/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078055618 CMS
AstraZeneca Pharmaceuticals LP $13.8703/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104449515 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.9703/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118112953 CMS
Kiniksa Pharmaceuticals International, plc $39.6103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154886653 CMS
PFIZER INC. $10.0803/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131440459 CMS
Merck Sharp & Dohme LLC $17.6102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141648928 CMS
SCPHARMACEUTICALS INC. $17.2002/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132255153 CMS
Novartis Pharmaceuticals Corporation $20.1302/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086868073 CMS
E.R. Squibb & Sons, L.L.C. $9.4102/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101238352 CMS
AstraZeneca Pharmaceuticals LP $15.8102/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104536243 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.3802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118112955 CMS
Amgen Inc. $13.7302/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111573350 CMS
Janssen Pharmaceuticals, Inc $16.2702/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078055652 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,413.53 72
PY2020 $713.52 43
PY2021 $1,267.10 71
PY2022 $1,534.30 77
PY2023 $1,273.79 54
PY2024 $2,481.54 114
PY2025 $2,075.79 88

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $29,211.18 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 12/25/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737614
Principal investigator 1 Boehringer Ingelheim International GmbH $21.75 12/25/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737616
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 12/25/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737618
Principal investigator 1 Boehringer Ingelheim International GmbH $780.00 10/06/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737602
Principal investigator 1 Boehringer Ingelheim International GmbH $4,000.00 10/06/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737610
Principal investigator 1 Boehringer Ingelheim International GmbH $1,900.00 10/02/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737600
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/02/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737604
Principal investigator 1 Boehringer Ingelheim International GmbH $2,043.00 10/02/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737606
Principal investigator 1 Boehringer Ingelheim International GmbH $10,000.00 10/02/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737608
Principal investigator 1 Boehringer Ingelheim International GmbH $1,800.00 10/02/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737612
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 06/26/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220997714
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737594
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 06/24/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737596
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Pulse Cardiology
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220737598